Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell ...
At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
Morning Overview on MSN
Disabling NFIL3 via CRISPR kept engineered CAR T-cells from hitting exhaustion, prolonging tumor control in animal models
Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the transcription factor NFIL3 in engineered CAR T cells, and the modified ...
A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their ...
The immune system is made up of different types of cells, which have different roles in protecting the body from infection. One type of immune cell called a B cell creates antibodies that attack ...
Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...
LONDON, UK / ACCESSWIRE / January 8, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), which is developing new therapies and treatments for blood diseases, is pleased to announce the successful ...
Exton, PA, May 21, 2026 (GLOBE NEWSWIRE) -- Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new findings from Spherix Global Insights suggest that operational and logistical ...
Formation of an immunological synapse (gray) between CAR-T cells, which are specially equipped to express the CCR7 receptor(cyan), and tumor cells (magenta). The CAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results